These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28413387)

  • 1. Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.
    Bilgiç Temel A; Bassorgun CI; Akman-Karakaş A; Alpsoy E; Uzun S
    Case Rep Dermatol; 2017; 9(1):38-44. PubMed ID: 28413387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
    James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
    Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
    Messingham KN; Pietras TA; Fairley JA
    G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullous Diseases.
    Corbaux C; Joly P
    Curr Probl Dermatol; 2018; 53():64-69. PubMed ID: 29131038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid.
    Kwon IJ; Kim T; Yoo DS; Min S; Kim SC; Kim JH
    J Dermatol; 2023 May; 50(5):705-709. PubMed ID: 36514846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.
    Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V
    Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab.
    Sinha S; Agrawal D; Sardana K; Kulhari A; Malhotra P
    Indian Dermatol Online J; 2020; 11(4):607-611. PubMed ID: 32832453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
    Cao P; Xu W; Zhang L
    Front Immunol; 2022; 13():928621. PubMed ID: 35769474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature.
    Balakirski G; Alkhateeb A; Merk HF; Leverkus M; Megahed M
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1778-1782. PubMed ID: 27357866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological treatment for bullous pemphigoid.
    Oren-Shabtai M; Mimouni D; Nosrati A; Atzmony L; Kaplan B; Barzilai A; Baum S
    Front Immunol; 2023; 14():1157250. PubMed ID: 37180101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.
    Kremer N; Snast I; Cohen ES; Hodak E; Mimouni D; Lapidoth M; Mazor S; Levi A
    Am J Clin Dermatol; 2019 Apr; 20(2):209-216. PubMed ID: 30421306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].
    Neumark M; Tal Y; Zlotogorski A; Molho-Pessach V
    Harefuah; 2020 Jan; 159(1):29-30. PubMed ID: 31930804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
    Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin E and bullous pemphigoid.
    Cozzani E; Gasparini G; Di Zenzo G; Parodi A
    Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety.
    D'Aguanno K; Gabrielli S; Ouchene L; Muntyanu A; Ben-Shoshan M; Zhang X; Iannattone L; Netchiporouk E
    J Cutan Med Surg; 2022; 26(4):404-413. PubMed ID: 35379011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab in the treatment of bullous pemphigoid: A single-center series of 15 cases.
    Altan Ferhatoglu Z; Yucesoy SN; Ak T; Demir Y
    Medicine (Baltimore); 2024 Jul; 103(30):e38684. PubMed ID: 39058846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy of recalcitrant bullous dermatoses.
    Wollina U; Koch A; Hansel G
    J Dermatol Case Rep; 2008 Mar; 2(1):4-7. PubMed ID: 21886702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200.
    Yalcin AD; Genc GE; Celik B; Gumuslu S
    Clin Lab; 2014; 60(3):523-4. PubMed ID: 24697134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches.
    Toh WH; Lee HE; Chen CB
    Front Med (Lausanne); 2023; 10():1196946. PubMed ID: 37614956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.